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Summary Sporadic cases have developed pulmonary toxicity after receiving chemotherapy and granulocyte colony-stimulating factor
(G-CSF). However, because such cases received chemotherapy that alone frequently causes pulmonary toxicity, the role of G-CSF in this
toxicity has been unclear. CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) only slightly induces pulmonary
toxicity. However, we observed a considerable incidence of this toxicity in non-Hodgkin's lymphoma subjects receiving CHOP therapy and
G-CSF (6 out of 52 subjects, 11.5%). In this cohort, among various characteristics, including the dose and interval of CHOP therapy, only the
mean peak leucocyte count (MPLC) with each therapy cycle was associated with development of this toxicity (MPLC . 23.0 x 109 I-, 6 out of
29 cases; MPLC < 23.0 x 109 I-', 0 out of 23 cases; P= 0.020). These findings suggest that the effect of G-CSF is the main determinant of the
pulmonary toxicity in these cases. Because the toxicity was associated with a large MPLC and did not recur in cases readministered G-CSF,
an idiosyncratic reaction to G-CSF is unlikely to be the pathogenesis of this toxicity. Thus, lowering the G-CSF dose seems to be useful in the
prevention of this toxicity. In all six cases, the time course of manifestation of the toxicity was the same, and early application of high-dose
corticosteroid led to cure. This knowledge will be helpful in the care of similar cases.
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Granulocyte colony-stimulating factor (G-CSF) has been used to
accelerate neutrophil recovery after chemotherapy for various
neoplasms. Sporadic cases have developed pulmonary toxicity after
receiving chemotherapy and G-CSF (Iki et al, 1993; Katoh et al,
1993; Matthews, 1993; Dirix et al, 1994; Lei et al, 1994). The
pulmonary toxicity ofchemotherapeutic drugs has been attributed, at
least in part, to the production ofreactive oxygen species thatdamage
the pulmonary epithelium and induce an influx of peripheral
neutrophils (Kreisman et al, 1992). G-CSF increases the number and
the functional properties, such as superoxide production and expres-
sion of adhesion-related molecules, of neutrophils (Ohsaka et al,
1989). Therefore, it may be speculated that G-CSF has a causal
association with the pulmonary toxicity, e.g. by augmenting the
pulmonary damage caused by chemotherapeutic drugs.
However, there is no full consensus that G-CSF is involved in
the development of pulmonary toxicity (Bastion et al, 1994a and
b). Even in a recent detailed review of G-CSF in clinical practice,
pulmonary toxicity was not mentioned (Welte et al, 1996). This
is probably because (1) the above sporadic cases received a
chemotherapy regimen that can cause pulmonary toxicity without
G-CSF (some regimens show pulmonary toxicity in nearly 20% of
cases without G-CSF; Shapiro et al, 1991) and (2) in all clinical
studies in which G-CSF and a placebo were randomized for
patients receiving chemotherapy, the incidence of pulmonary
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toxicity did not differ between the treatment groups (Bastion
etal, 1994a).
In this study, we analysed the incidence of pulmonary toxicity
and the characteristics of patients who did or did not develop
pulmonary toxicity when administered chemotherapy and G-CSF.
The statistical data presented here indicate that G-CSF is indeed
associated with the development of pulmonary toxicity. We also
present data that represent a clue for prevention, early detection
and treatment ofG-CSF-associated pulmonary toxicity.
PATIENTS AND METHODS
The subjects were 52 patients with newly diagnosed non-
Hodgkin's lymphoma (NHL) who were treated with CHOP
therapy [cyclophosphamide (CPA, 750 mg m-2 on day 1), doxoru-
bicin (DOX, 50 mg m-2 on day 1), vincristine (VCR, 1.4 mg m-2
(maximum 2 mg) on day 1) and prednisolone (PSL 50 mg m-2 on
days 1-5)] and G-CSF. They were all consecutive aggressive NHL
cases and some cases oflow-grade NHL treated in our department
during the 1992-96 period. To increase the dose intensity of the
therapy, all subjects received subcutaneous injection of G-CSF,
usually from day 3 to day 12 of each therapy cycle. This enabled
the chemotherapy to be given every 2 weeks in most cases.
The clinical files ofall cases were re-evaluated for drug-induced
pulmonary toxicity. The diagnosis of drug-induced pulmonary
toxicity was confirmed based on findings including a non-produc-
tive cough, unexplained fever, elevated serum C-reactive protein
(CRP) level, hypoxaemia, interstitial lung shadow on radiographs
and computerized tomography (CT) films, and repeatedly negative
results for micro-organisms in the sputum, blood and bronchoalve-
olar lavage (BAL) fluid. Evaluation for micro-organisms included
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Table 1 NHL patients who developed pulmonary toxicity during the G-CSF-
combined CHOP therapy
Case Age (years)/ Histology/ CHOP Toxicity
no. gender stagea cycleb grade Therapyc
1 67/M DSC/IVA 3 4 mPSL
2 62/F ND/lIlA 5 4 mPSL
3 63/M DUIIIA 4 4 mPSL
4 55/M IBUIIIB 6 4 mPSL
5 24/F DUIVB 4 3 mPSL
6 48/M DUIIIB 2 2 PSL
aHistological classification (the Working Formulation) and clinical stage of
NHL. DSC, diffuse, small cleaved cell; DL, diffuse, large cell; IBL, large cell,
immunoblastic; ND, not determined. bNumber of cycles of the G-CSF-
combined CHOP therapy until the lung toxicity developed. cTherapy for the
pulmonary toxicity. mPSL, methylprednisolone; PSL, prednisolone.
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microscopic examination, culture study, polymerase chain reaction
(PCR) analysis (Mycobacterium tuberculosis and Pneumocystis
carinii) and serological tests (fungi and cytomegalovirus). The
pulmonary toxicity was graded on the Eastern Cooperative
Oncology Group (ECOG) scale (Oken et al, 1982). Briefly, grade
1 refers to mild symptoms, a 25-50% decrease in DLCO; grade 2
refers to moderate symptoms, a more than 50% decrease in
DLCO; grade 3 refers to severe symptoms with an intermittent
requirement for oxygen; grade 4 refers to a requirement for
assisted ventilation or continuous oxygen; and grade 5 refers to
death due to the toxicity.
In these 52 cases, various clinical variables were compared
between the patients who developed drug-induced pulmonary
toxicity and those who did not. The cardinal variables evaluated
are listed in Table 2. The data on these variables were available for
all 52 cases except for the serum soluble interleukin 2 level (sIL-
2R), which was available for all six patients who developed
pulmonary toxicity and 13 patients who did not. The nadir and
peak leucocyte counts for each patient are the mean of the lowest
and highest leucocyte counts in each therapy cycle respectively.
The Mann-Whitney U-test was used for comparison of the data
for continuous variables, and a 2 x 2 table (chi-square test) was
used for comparison ofthe data for categorical variables.
All NHL patients administered the same CHOP regimen (every
3 weeks) without G-CSF between 1985 and 1991 in our depart-
ment (49 patients) were also evaluated for the development of
pulmonary toxicity.
RESULTS
Incidence and clinical course of pulmonary toxicity in
cases treated with CHOP therapy and G-CSF
Six of the 52 cases (11.5%) developed drug-induced pulmonary
toxicity (Table 1). None ofthem had risk factors for drug-induced
pulmonary toxicity, i.e. underlying lung disease including invasion
by NHL, prior oxygen therapy, prior radiotherapy or other
chemotherapy. In all six cases, the toxicity developed when the
NHL had responded well to the therapy. The time course of the
clinical manifestations of the pulmonary toxicity was essentially
the same in all cases, as illustrated in Figure 1. During the leuco-
cyte recovery phase preceding the CHOP course associated with
the pulmonary toxicity, four of the six cases developed an unex-
plained low-grade fever and an elevated serum CRP level. These
Figure 1 Time course of clinical manifestations of pulmonary toxicity. The
leucocyte counts are expressed as the range in the six cases. The
arrowheads indicate the starting day of each CHOP therapy
A
B
Figure 2 Interstitial lung shadow revealed by (A) chest radiography and
(B) chest CT scan of case 1
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findings had not been observed during the prior CHOP courses.
Seven and a half days (median) after the start of the next CHOP
course, all six cases developed a low-grade fever with an elevated
serum CRP level. At that time, only one of the six cases had
neutropenia (0.9 x 109 1-'), and the median neutrophil count for the
six cases was 7.2 x 1091-1. During the subsequent clinical course,
only two cases (including the above neutropenic case) had
neutropenia (< 1 x 1091-'), whose duration was only 2 days in both
cases. In all cases, a high-grade fever and hypoxaemia with an
interstitial lung shadow on the CT scan and/or chest radiography
developed 5 and 9 days (median) after the first day of this low-
grade fever respectively. CT scanning was better able to detect the
interstitial lung shadow in most cases. A non-productive cough
and fine crackles on chest examination developed in four and two
cases, respectively, usually after the hypoxaemia had developed.
Eosinophilia was not observed in any cases. The radiological films
of a representative case are shown in Figure 2.
All cases were initially treated with antibiotics, with or without
an antifungal agent empirically. However, because this therapy
was ineffective, and micro-organisms were not detected in
repeated examinations, it was replaced with corticosteroid therapy.
Five cases were treated with 1 g of methylprednisolone daily for
3 consecutive days, followed by prednisolone (PSL) (1 mg kg-')
daily, which was reduced according to the clinical response. The
remaining one case was treated with PSL (1 mg kg-') daily from
the beginning. The pulmonary disease ofall six cases was resolved
by the corticosteroid therapy. Lymphocyte transformation tests
using CPA, DOX, VCR and G-CSF were performed in five of the
six cases. The results were all negative except for a weakly posi-
tive response to CPA in case 5. After the lung toxicity had been
resolved, two of the six cases (cases 2 and 3) were readministered
G-CSF with a different chemotherapeutic regimen, in which the
dose and duration of G-CSF were minimized (the leucocyte count
did not exceed 5 x 1091-'). The pulmonary toxicity did not recur.
We then compared the incidence ofpulmonary toxicity between
the present G-CSF combined CHOP therapy and the standard
CHOP therapy consisting of the same chemotherapeutic drugs and
doses given every 3 weeks without G-CSF. Our literature review
found almost no reports of symptomatic pulmonary toxicity in
NHL patients treated with the CHOP therapy (McKelvey et al,
1976; Jones et al, 1983; Shapiro et al, 1991; Fisher et al, 1993).
The exception was a study that reported that 5 out of 174 patients
(3%) developed mild pulmonary toxicity (ECOG grade 1 or 2) and
2 out of 174 patients (1I%) showed severe lung toxicity (Gordon et
al, 1992). Even compared with the results of this report, our
present G-CSF combined CHOP therapy showed a significantly
higher incidence ofpulmonary toxicity (subjects with any toxicity
grade, 7 out of 174 vs 6 out of 52, P = 0.04; subjects with severe
toxicity grade (ECOG grades 3-5), 2 out of 174 vs 5 out of 52,
P = 0.002). We also note that none of the 49 NHL patients we
treated with CHOP therapy without G-CSF, between 1985 and
1991, developed pulmonary toxicity.
Comparison of characteristics between subjects who
did/did not develop pulmonary toxicity (Table 2)
In the 52 patients who received the G-CSF-combined CHOP
therapy, there were no significant differences in the pretreatment
characteristics between the subjects who developed pulmonary
toxicity and those who did not. Although the pulmonary toxicity
Table 2 Comparison of characteristics between subjects who developed
lung toxicity and subjects who did not
Lung toxicity
Positive (n = 6) Nega
Pretreatment characteristics
Age (years)
Gender (M/F)
NHLa
Grade (H/l/UM)
Phenotype (B/T)
Stage (1/11/111/IV)
Serum level
LDH (IU I-')
slL-2R (U ml-')
CRP (mg 100 ml-')
Therapyb
Cycle
Interval (days)
Drugs
CPA (mg m-2)
DOX (mg m-2)
VCR (mg m-2)
PSL (mg m-2)
G-CSF (ug kg-'
Leucocyte countc
Nadir value (x 109 I-')
Peak value (x 109 I-')
Occurrence of lung toxicity
as a function of peak value
Peak value > 23.0 x 109 1-'
Peak value < 23.0 x 109 1-'
53.2 + 15.8
4/2
1/3/1/1
5/1
0/0/4/2
856 ± 790
2870 + 1449
4.1 +3.8
4.0+ 1.4
14.6 + 0.7
720 ± 103
48 ± 7
1.2 ± 0.3
255 ± 12
22.8 ± 6.9
2.9+ 1.4
29.5 ± 5.0d
6e
0
itive(n = 46)
52.8 + 15.3
22/24
1/34/8/3
36/10
2/7/17/20
725 + 831
3212 + 2035
4.6 + 6.0
5.3 + 2.1
15.0 + 3.2
700 + 115
47+7
1.2 + 0.2
236+ 27
19.3 + 5.5
3.2 ± 2.0
23.2 + 8.5
23
23
Data are expressed as mean + s.d. or case number. aHistological grade by
the Working Formulation (H, high grade; 1, intermediate grade; L, low grade;
M, miscellaneous), immunophenotype (B, B-cell type; T, T-cell type) and
clinical stage. bAdministered therapy cycle, average interval between each
cycle and dose of drugs per therapy cycle. cDefinitions of the nadir and peak
values are described in Patients and methods. dp= 0.048 (Mann-Whitney
U-test). ep= 0.020 (X2 test). LDH, lactate dehydrogenase.
developed only in subjects with advanced NHL (stage III or IV),
this was not statistically significant (P > 0.2). The subjects who
developed pulmonary toxicity received a slightly smaller number
of therapy cycles compared with the other subjects (P> 0.1). The
doses ofchemotherapeutic drugs and G-CSF per therapy cycle and
the therapy interval did not differ between the two groups. The
only difference was the peak leucocyte count. The subjects who
developed pulmonary toxicity had a significantly higher peak
leucocyte count than the subjects who did not (P = 0.048). Further,
the pulmonary toxicity developed only in subjects who had a peak
leucocyte count above 23.0 x 109 1-' (. 23.0 x 1091-, 6 out of 29
subjects (21%); < 23.0 x 1091-, 0 out of 23 subjects). This differ-
ence was statistically significant (P = 0.020). Exactly the same
results were obtained when the peak neutrophil count was used for
the analysis instead ofthe peak leucocyte count (P = 0.020 at a cut-
offpeak neutrophil count of 20.0 x 109 I-').
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DISCUSSION
The diagnosis of drug-induced pulmonary toxicity in the present
cases is supported by the following findings: significant
neutropenia was not observed when the pulmonary symptoms
developed; repeated tests for micro-organisms were negative;
there was probably no pulmonary invasion by the NHL (none of
the six cases had pulmonary invasion by NHL before the CHOP
therapy, and interstitial lung disease developed when the NHL
responded well to the CHOP therapy); interstitial lung disease
developed with the same time course; and all cases were success-
fully treated with corticosteroids. In almost all of the previously
reported cases who developed pulmonary toxicity after receiving
chemotherapy and G-CSF, the applied chemotherapy alone can
cause pulmonary toxicity at a considerable incidence (Iki et al,
1993; Katoh et al, 1993; Matthews, 1993; Okubo et al, 1993; Dirix
et al, 1994: Lei et al. 1994; Niitsu et al, 1995). Therefore, the
contribution of G-CSF to the pulmonary toxicity in these prior
cases is difficult to define clearly. Meanwhile, our literature review
indicated that the standard CHOP therapy, given every 3 weeks
without G-CSF. does not cause pulmonary toxicity. Or, if it does,
the induced toxicity is usually mild and observed in a small
percentage of patients. The same conclusion was reached by a
review by other authors (Shapiro et al, 1991). It is also noted that
none of our NHL patients treated with the standard CHOP therapy
without G-CSF developed pulmonary toxicity. In contrast, the
present G-CSF-combined CHOP therapy given every 2 weeks
showed a significantly higher incidence of pulmonary toxicity
compared with the standard CHOP therapy.
The above findings indicate that G-CSF and/or the increased
dose intensity of the chemotherapy, which was enabled by the G-
CSF usage, were associated with the development of pulmonary
toxicity in our cases. Further, ofthe total 52 patients who received
the G-CSF-combined CHOP therapy, the dose and interval of
CHOP therapy did not differ between the subjects who developed
pulmonary toxicity and those who did not. Also, the number of
CHOP therapy cycles was slightly smaller in the former group. On
the other hand, a high peak leucocyte count showed a statistically
significant association with the development of pulmonary toxi-
city; the toxicity developed only in subjects who had a peak leuco-
cyte count above 23.0 x 109 1-' (6 out of 29 subjects, 21%). These
findings suggest that the effect of G-CSF, not the CHOP dose
intensity, was the main determinant of the development of
pulmonary toxicity in the present cases. These data also allow
speculation that, in addition to differences in the chemotherapy
(kinds ofdrugs and number ofcycles), the difference in the degree
of G-CSF-induced leucocytosis may explain why G-CSF-associ-
ated pulmonary toxicity was not apparent in earlier randomized
studies (Bastion et al, 1994a).
Based on the present data, we speculate two possible mecha-
nisms for the development of pulmonary toxicity in G-CSF-
combined chemotherapy. First, an increased number of
functionally activated neutrophils may play a role (such as by
releasing reactive oxygen) in the development oflung damage that
probably has already been initiated subclinically by the adminis-
tered chemotherapeutic drugs. We performed BAL in four out of
six cases who developed pulmonary toxicity, and lymphocytes, not
neutrophils, were the predominant cells in the BAL fluid in all
cases (data not shown). This finding may conflict with this mecha-
nism. However, because the BAL fluid does not necessarily reflect
the interstitial cell components (Lugano et al, 1982; Paradis et al,
1986), there is a possibility that neutrophils accumulated in the
interstitial tissue and caused the pulmonary damage. The second
mechanism is based on the concept that the subjects who had a
higher peak leucocyte count during the therapy may merely be an
indication that the biological effect ofG-CSF was stronger in these
subjects compared with the other subjects. Besides granulopoiesis,
various actions of G-CSF that are not mediated by neutrophils
have been reported, some of which may contribute to the patho-
genesis of lung diseases and tissue fibrosis (Vaillant et al. 1993;
Pei et al, 1996). Therefore, G-CSF may exacerbate the lung
damage caused by chemotherapy without mediation by
neutrophils in subjects with a high peak leucocyte count (i.e. due
to a strong biological effect of G-CSF). As shown in Figure 1,
when the symptoms of pulmonary toxicity developed, the peak
leucocyte count had passed, but G-CSF continued to be adminis-
tered. This finding may support the second mechanism proposed
above. However, the first mechanism is still possible because PSL
in the CHOP therapy (given on days 1-5) may simply delay the
development of clinically apparent pulmonary toxicity, which
appeared 7.5 days (median) after starting the CHOP therapy. An
idiosyncratic reaction to G-CSF is a very unlikely mechanism for
the pulmonary toxicity in the present cases. This is because the
toxicity was associated with a high leucocyte count, the toxicity
did not recur in two cases who were readministered G-CSF, and
the lymphocyte transformation response to G-CSF was negative.
The pulmonary toxicity that develops after G-CSF-combined
chemotherapy may be fatal (Iki et al, 1993; Katoh et al, 1993).
Therefore, prevention, early detection and proper treatment of such
cases is extremely important. Assuming that an idiosyncratic mech-
anism is very unlikely, dose modification ofG-CSF seems useful for
preventing this toxicity. Our data on the peak leucocyte count indi-
cate that the G-CSF dose should be limited to assure that the leuco-
cyte count does not exceed 23.0 x 109 1-' in the G-CSF-combined
CHOP therapy. In other protocols using different combinations and
doses of chemotherapeutic drugs, the optimal limit for the G-CSF
dose to prevent pulmonary toxicity may differ. To verify this point,
various data, including the peak leucocyte count with each cycle of
therapy and the G-CSF dose, should be compared between the
subjects who did and did not develop toxicity on other protocols. To
date, detailed data ofsuch analyses are not available in the literature.
We believe that the time course ofthe clinical manifestations shown
in Figure 1 will aid in the diagnosis ofpulmonary toxicity associated
with G-CSF-combined chemotherapy. Further, our data suggest that,
if G-CSF-associated pulmonary toxicity develops, early application
of high-dose corticosteroid deserves to be considered in addition to
discontinuation ofG-CSF.
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